Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hybrid Radiotherapy with Immunotherapy in Metastatic NSCLC
NCT06313541Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2024
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Fudan University. Primary endpoint: Progression Free Survival at 2 years. Started Apr 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06313541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06313541.